Article: OGS Separating Business Into Three Units To Aid Transparency.

Washington Editor

Under the direction of a new CEO, Oxford GlycoSciences plc released a plan Thursday to reduce its burn rate and improve performance by dividing its business into three separate units.

Located in Oxford, UK, OGS intends to become a research and development-based company with a focus on products for oncology and inherited storage disorders, supported by a proteomics division, David Ebsworth, OGS's CEO, told BioWorld Today.

Formerly the global head of pharmaceuticals at Bayer AG, of Leverkusen, Germany, Ebsworth came on board as OGS CEO July 1, replacing Michael Kranda, who resigned for personal reasons. In announcing the ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!